New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
New biomarker advances cancer treatments

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n
Oncology November 21,2023
New biomarker advances cancer treatments

New biomarker advances cancer treatments

Researchers have discovered ways to enhance NIR-PIT to ensure tumours are treated sufficiently and improve patient outcomes.A biomarker based on microbubbles has been used to evaluate the success of n
Oncology November 21,2023
Expert Discusses Transplant and Emerging Strategies in Myeloma

Expert Discusses Transplant and Emerging Strategies in Myeloma

October 5, 2018Brandon ScaleaThomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.Thomas G. Martin, MDTho
World medicine November 21,2023
Expert Discusses Transplant and Emerging Strategies in Myeloma

Expert Discusses Transplant and Emerging Strategies in Myeloma

October 5, 2018Brandon ScaleaThomas G. Martin, MD, discusses the clinical utility of autologous stem cell transplantation and the rapidly evolving treatment paradigm of myeloma.Thomas G. Martin, MDTho
World medicine November 21,2023
Expert Sheds Light on Role of Combinations, Transplant in Myeloma

Expert Sheds Light on Role of Combinations, Transplant in Myeloma

October 27, 2017Angelica WelchJayesh Mehta, MD, discusses combination therapies in multiple myeloma, as well as the continued importance of stem cell transplant.Jayesh Mehta, MDWith a plethora of comb
World medicine November 21,2023
Expert Sheds Light on Role of Combinations, Transplant in Myeloma

Expert Sheds Light on Role of Combinations, Transplant in Myeloma

October 27, 2017Angelica WelchJayesh Mehta, MD, discusses combination therapies in multiple myeloma, as well as the continued importance of stem cell transplant.Jayesh Mehta, MDWith a plethora of comb
World medicine November 21,2023
Antibodies From Cured AML Patients Kill Leukemia Cells

Antibodies From Cured AML Patients Kill Leukemia Cells

June 12, 2016Jason M. BroderickPatients with acute myeloid leukemia who are cured after allogeneic hematopoietic stem cell transplantation produce antibodies that destroy leukemia cells.Mette D. Hazen
World medicine November 21,2023
Antibodies From Cured AML Patients Kill Leukemia Cells

Antibodies From Cured AML Patients Kill Leukemia Cells

June 12, 2016Jason M. BroderickPatients with acute myeloid leukemia who are cured after allogeneic hematopoietic stem cell transplantation produce antibodies that destroy leukemia cells.Mette D. Hazen
World medicine November 21,2023
Hematopoietic Stem Cell Transplant: A Viable Option for Older Patients With AML

Hematopoietic Stem Cell Transplant: A Viable Option for Older Patients With AML

March 27, 2020Mark B. Juckett, MDThe challenge in caring for older patients is developing a risk-adapted strategy that best meets the patients’ identified goals and accounts for a realistic assessment
World medicine November 21,2023
Hematopoietic Stem Cell Transplant: A Viable Option for Older Patients With AML

Hematopoietic Stem Cell Transplant: A Viable Option for Older Patients With AML

March 27, 2020Mark B. Juckett, MDThe challenge in caring for older patients is developing a risk-adapted strategy that best meets the patients’ identified goals and accounts for a realistic assessment
World medicine November 21,2023
Carving Out New Combination Therapies in Stem Cell Disorders

Carving Out New Combination Therapies in Stem Cell Disorders

July 13, 2020Caroline SeymourDespite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.William B. Donnellan,
World medicine November 21,2023
Carving Out New Combination Therapies in Stem Cell Disorders

Carving Out New Combination Therapies in Stem Cell Disorders

July 13, 2020Caroline SeymourDespite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.William B. Donnellan,
World medicine November 21,2023
Prophylactic Letermovir Limits CMV Infections Post-Transplantation

Prophylactic Letermovir Limits CMV Infections Post-Transplantation

February 26, 2017Silas InmanProphylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following
World medicine November 21,2023
Prophylactic Letermovir Limits CMV Infections Post-Transplantation

Prophylactic Letermovir Limits CMV Infections Post-Transplantation

February 26, 2017Silas InmanProphylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following
World medicine November 21,2023
Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma

Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma

June 24, 2017Virginia Powers, PhDPatients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as tho
World medicine November 21,2023
Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma

Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma

June 24, 2017Virginia Powers, PhDPatients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as tho
World medicine November 21,2023
Protein-triggered motor neuron loss in amyotrophic lateral sclerosis

Protein-triggered motor neuron loss in amyotrophic lateral sclerosis

The intricate control of our bodily movements relies on a network of neural pathways connecting the brain and spinal cord. Key among these pathways is the transmission of commands from neurons in the
World medicine November 21,2023
Protein-triggered motor neuron loss in amyotrophic lateral sclerosis

Protein-triggered motor neuron loss in amyotrophic lateral sclerosis

The intricate control of our bodily movements relies on a network of neural pathways connecting the brain and spinal cord. Key among these pathways is the transmission of commands from neurons in the
World medicine November 21,2023
First-Line Dose-Dense Induction and High-Dose Chemotherapy/Autologous Stem Cell Transplant Benefits Patients With Rare Lymphomas

First-Line Dose-Dense Induction and High-Dose Chemotherapy/Autologous Stem Cell Transplant Benefits Patients With Rare Lymphomas

October 8, 2012Jill SteinDose-dense induction with high-dose chemotherapy/autologous stem-cell transplantation is reasonable for use as first-line treatment of transplantation-eligible patients with s
World medicine November 21,2023
First-Line Dose-Dense Induction and High-Dose Chemotherapy/Autologous Stem Cell Transplant Benefits Patients With Rare Lymphomas

First-Line Dose-Dense Induction and High-Dose Chemotherapy/Autologous Stem Cell Transplant Benefits Patients With Rare Lymphomas

October 8, 2012Jill SteinDose-dense induction with high-dose chemotherapy/autologous stem-cell transplantation is reasonable for use as first-line treatment of transplantation-eligible patients with s
World medicine November 21,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com